Press Releases

You Narrowed By: Business/Product Release

Showing 141-174 of 174

First Prev 1 2 3 4 5 Last

2011
May
May 20	Abbott Introduces New ZonePerfect® Sweet & Salty Nutrition Bars
May 19	Abbott Statement on the FDA Advisory Committee Recommendations on Fenofibric Acid
May 18	Abbott Receives FDA Approval for Molecular Test for Hepatitis C
May 18	Study Shows Improved Patient Management and Outcome using Abbott’s Sensitive Troponin Assay
May 14	Abbott Features Novel Biomarkers and Laboratory Automation at International Federation of Clinical Chemistry Congress
May 10	Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System with Insulin Calculator Receives CE Mark
May 10	Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
May 6	Abbott Receives FDA Approval to Expand Use of the RX ACCULINK® Carotid Stent System to Patients at Standard Surgical Risk

April
April 29	Abbott Highlights Top-Tier Financial Performance, Strong Growth in Emerging Markets at Annual Meeting
April 29	Abbott Receives U.S. FDA Approval for AndroGel® 1.62% to Treat Men with Low Testosterone
April 15	New Fully Automated Vitamin D Assay Submitted for FDA Clearance
April 12	Abbott Recognized As Company of the Year for Global Halal Initiatives
April 4	Data from Landmark Clinical Trial of Abbott's MitraClip® System Demonstrate Durable Clinical Benefits for Patients with Mitral Regurgitation Two Years After Treatment
April 4	Abbott's ABSORB Bioresorbable Vascular Scaffold Demonstrates Positive One-Year Safety and Efficacy Results
April 4	Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
April 3	Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

March
March 31	Abbott Introduces Hepatitis B Sequencing Test in Europe
March 30	Abbott Announces Launch of Catheter-Based MitraClip® System in Australia for Mitral Regurgitation, the Most Common Heart Valve Condition
March 28	Abbott Introduces Micro-Implantation Cataract Suite
March 21	Abbott's New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults
March 4	Positive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease Published in the Journal of the American Society of Nephrology

February
February 22	Abbott Launches a CE Marked KIF6 Test in Europe
February 7	Abbott Introduces Biothreat Assay for PLEX-ID™ System
February 7	Abbott’s Ibis Technology Identified Fatal Disease Organism in Afghanistan

January
January 31	Abbott's TREK® Coronary Balloon System Now Available in the United States and Japan
January 26	FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott's Carotid Stent System to Include Patients at Standard Surgical Risk
January 25	New Abbott Vitamin D Test Available for Use in the European Union
January 10	Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
2010
September
September 23	Abbott's XIENCE V® Shows Outstanding Two-Year Clinical Results Versus TAXUS® in Key Safety and Efficacy Measures in SPIRIT IV Trial

May
May 25	Abbott's Investigational MitraClip® System Demonstrates Strong Safety Results and Improved Clinical Outcomes for Common Causes of Leaky Heart Valves

March
March 14	New Data Demonstrates Abbott's Investigational MitraClip® System Has Potential to be a Valuable Treatment Option for Patients with Mitral Regurgitation, the Most Common Heart Valve Condition
2009
November
November 2	Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes

August
August 31	Abbott Launches Next-Generation XIENCE PRIME™ Drug Eluting Stent in International Markets

June
June 12	Abbott Announces Launch of Next-Generation Embolic Protection System

First Prev 1 2 3 4 5 Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.